Karuna Therapeutics, Inc. Common Stock
KRTX
KRTX: Karuna Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies to address disabling neuropsychiatric conditions characterized by unmet medical needs. Its product candidate, KarXT is an oral modulator of muscarinic receptors that are located both in the central nervous system, or CNS, and various peripheral tissues.
moreShow KRTX Financials
Recent trades of KRTX by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Daniel Goldman House / D | Sale $1,001 - $15,000 | Apr. 10, 2023 |
Recently reported changes by institutional investors
Quarterly net insider trading by KRTX's directors and management
Government lobbying spending instances
New patents grants
-
Patent Title: Xanomeline derivatives and methods for treating neurological disorders Dec. 27, 2022
-
Patent Title: Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Oct. 18, 2022
-
Patent Title: Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Sep. 27, 2022
-
Patent Title: Compositions and methods for treating disorders ameliorated by muscarinic receptor activation Mar. 02, 2021
-
Patent Title: Compositions and methods for treatment of disorders ameliorated by muscarinic receptor activation Feb. 23, 2021
Federal grants, loans, and purchases
Followers on KRTX's company Twitter account
Number of mentions of KRTX in WallStreetBets Daily Discussion
Recent insights relating to KRTX
Recent picks made for KRTX stock on CNBC
ETFs with the largest estimated holdings in KRTX
Flights by private jets registered to KRTX